Hearscape
← Organizations
Company

Decibel Therapeutics

Company-level hearing-loss landscape profile across checked programs, evidence quality, modalities, indications, and open data checks.

All ProgramsTherapeuticsDevices
Open filtered programs
Programs
2
linked to organization
Strong Evidence
1
2 status confirmed
Details Checked
2
0 open data checks
Company / Institution Links
2 / 0
industry vs non-industry records
Competitive Density
3
Pipeline Velocity
15
Completion Signal
100

Programs by Stage

Phase 11
Approved1

Trial / Program Status

Approved1
Completed1

Modality Mix

Drug Delivery1
Gene Therapy1

Indication Coverage

Hearing Loss2
Auditory Neuropathy1
Cisplatin-Induced Hearing Loss1
Genetic Hearing Loss1
OTOF-Related Hearing Loss1
Sensorineural Hearing Loss1

Program Types

Therapeutic2

Population Tags

adult2
bilateral1
cisplatin-ototoxicity1
congenital1
genetic1
otof-dfnb91
pediatric1
pre-lingual1
profound1

Strong-Evidence Records

1 records
Otarmeni by Regeneron
Strong evidence
Gene TherapyApprovedApproved

Dual-AAV intracochlear gene replacement delivers functional OTOF to cochlear inner hair cells to restore otoferlin-mediated auditory signaling.

Checked Records With Caveats

2 checked · 0 open checks
DB-020 by Regeneron and Decibel
Status confirmed
Drug DeliveryPhase 1Completed

Locally delivered thiosulfate formulation is injected through the eardrum to inactivate cisplatin in the cochlea while minimizing systemic tumor-protection risk.